Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Wearables' impact on cancer patients' quality of life to be tested

Project sees the Memorial Sloan Kettering Cancer Center collaborate with Medidata

Wearables pharma healthcare cancer 

A prestigious US cancer centre is set to evaluate the application of wearables and other mobile technology to assess cancer patients' quality of life.

The Memorial Sloan Kettering Cancer Center (MSK) is collaborating with cloud-based research solutions firm Medidata on the project, which will test the use of activity trackers and mobile apps to study patterns of movement in patients being treated for multiple myeloma.

Dr Neha Korde, assistant attending for the Myeloma Service at MSK, said: “All cancer patients face health challenges from the disease as well as the side effects of treatment. But the challenges are particularly acute for those who suffer from multiple myeloma, a painful blood cancer that affects the bones.

“We will be able to use mHealth technologies to gauge how patients sleep, how they move, and how they feel with greater precision.”

Patients taking part in the project at New York's MSK will be asked to wear a wearable activity tracker for one to seven days prior to treatment to establish baseline measurements, they will then be continuously for approximately four months over four cycles of the prescribed therapy.

They will also be able to report quality-of-life measures - such as activity level, fatigue and appetite - through Medidata's Patient Cloud ePRO app on their personal smart phones.

Medidata's president Glen de Vries said: “Success in cancer treatment is measured not just by what it does to the disease but what it does to the patient's body and mind. 

“Our collaboration with MSK will bring to bear the very best technology and data analytics to help researchers begin to identify multiple myeloma treatments that best enhance quality as well as quantity of life.”

Meanwhile, Medidata has expanded its relationship with Biogen, with the US biopharma company ramping up its use of the tech firm's Medidata Rave trial data capture product and its data verification tool Medidata TSDV.

The agreement expands an existing relationship to use Rave and TSDV across Biogen's clinical development portfolio, which includes potential therapies for neurological, autoimmune and rare diseases.

26th July 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics